Entellus Medical, Inc. (NASDAQ:ENTL) is set to release its earnings data after the market closes on Wednesday, November 1st.

Entellus Medical (NASDAQ:ENTL) last issued its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). Entellus Medical had a negative return on equity of 60.34% and a negative net margin of 41.11%. The firm had revenue of $22.10 million for the quarter, compared to analyst estimates of $21.87 million. During the same period in the previous year, the company earned ($0.27) earnings per share. Entellus Medical’s revenue for the quarter was up 18.0% compared to the same quarter last year. On average, analysts expect Entellus Medical to post $-1.62 EPS for the current fiscal year and $-0.92 EPS for the next fiscal year.

Entellus Medical, Inc. (NASDAQ ENTL) opened at 18.06 on Wednesday. The stock’s 50 day moving average price is $18.35 and its 200-day moving average price is $18.35. Entellus Medical, Inc. has a 12 month low of $11.47 and a 12 month high of $20.46. The firm’s market capitalization is $458.20 million.

A number of research analysts have recently commented on ENTL shares. Canaccord Genuity restated a “hold” rating and issued a $17.00 target price on shares of Entellus Medical in a research note on Tuesday, October 17th. Piper Jaffray Companies reiterated a “buy” rating and set a $21.00 price objective on shares of Entellus Medical in a research note on Tuesday, August 22nd. BidaskClub upgraded Entellus Medical from a “hold” rating to a “buy” rating in a research note on Saturday, August 19th. Finally, Zacks Investment Research upgraded Entellus Medical from a “sell” rating to a “buy” rating and set a $23.00 price objective for the company in a research note on Monday, October 9th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $21.86.

In other news, VP Kevin L. Mensink sold 2,500 shares of the business’s stock in a transaction on Friday, October 20th. The stock was sold at an average price of $19.00, for a total value of $47,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Brian E. Farley sold 40,000 shares of the business’s stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $19.78, for a total value of $791,200.00. The disclosure for this sale can be found here. Insiders have sold 92,150 shares of company stock valued at $1,740,652 in the last quarter. 7.70% of the stock is owned by company insiders.

An institutional investor recently raised its position in Entellus Medical stock. State Street Corp lifted its holdings in Entellus Medical, Inc. (NASDAQ:ENTL) by 26.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 140,856 shares of the medical technology company’s stock after purchasing an additional 29,386 shares during the quarter. State Street Corp owned 0.56% of Entellus Medical worth $2,333,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 70.27% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/10/25/entellus-medical-inc-entl-scheduled-to-post-earnings-on-wednesday.html.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Earnings History for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.